ALNY Q3 2023 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$751M+184.0% YoY

Gross Profit

$666M88.8% margin

Operating Income

$214M28.5% margin

Net Income

$148M19.7% margin

EPS (Diluted)

$1.15

QoQ Revenue Growth

+135.5%

Cash Flow

Operating Cash Flow

$359M

Free Cash Flow

$342M

Stock-Based Comp.

$64M

Balance Sheet

Total Assets

$3.8B

Total Liabilities

$4.0B

Stockholders' Equity

-$166M

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$751M	$264M	+184.0%
Gross Profit	$666M	$223M	+198.5%
Operating Income	$214M	-$258M	+182.9%
Net Income	$148M	-$406M	+136.4%

Revenue Segments

Product

$313M70%

ONPATTRO

$82M18%

GIVLAARI

$54M12%

Geographic Segments

UNITED STATES

$114M63%

Europe

$50M28%

Non-US Or Europe

$16M9%